Supplementary Methods

Identifying and estimating DDD unit values for conversion from SU to KG
Defined daily doses (DDDs) were calculated from kilogram data using the ATC/DDD index for 2016, developed by the WHO Collaborating Centre for Drug Statistics Methodology. DDD unit values were provided in the ATC/DDD index for 199 of the molecules in the IQVIA MIDAS database. When possible, DDD unit values not available through the ATC/DDD index were estimated from other sources (Supplementary Table 2 ). The DDD unit value for xibornol was identified through the MIMS Drug Information System, and the value for bacitracin was estimated using the conversion between international units and grams provided by etoolsage.com. For polymyxins, the sales data were not available in kilograms, so the largestselling polymyxin product worldwide was chosen as the reference product to generate DDD values using information from Falagas and Kasiakou (1). Specifically, we assumed that 1 SU = 1 vial which was assumed to contain 80 mg of colistimethate sodium (1). As the ATC/DDD index has 3 million IU for the DDD, we converted to IU using the conversion rate of 12,500 IU per mg of colistimethate sodium. The same conversion was used for polymyxin B parenteral administration. For the remaining molecules for which no DDD unit value was available, DDD unit value was estimated as the average value for each antibiotic class by route of administration (Supplementary Table 3 ). In addition, several molecules had a route of administration for which no DDD unit value was available or were combination drugs for which no DDD unit value was specified, in these cases the DDD was calculated as the average DDD of other routes (Supplementary Table 4 ). 
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Estimating total global antibiotic use in 2000-2015
Total global antibiotic use was predicted in DDDs. Population data for countries not included in the MIDAS database were retrieved from the World Development Indicators in the World Bank DataBank. Average per capita antibiotic consumption was calculated for each year and national income group. Total antibiotic use in countries not included in the IQVIA MIDAS database was estimated by multiplying the country's population in each year by this average. This method was also used to predict antibiotic use in countries included in the IQVIA MIDAS database that were missing antibiotic use data in all sectors for some years.
Predicting total global antibiotic use in 2015-2030
Total global antibiotic use in DDDs between 2015 and 2030 was predicted using three scenarios of future antibiotic use. Population projections were retrieved from the World Bank DataBank for all countries except Taiwan. Population projections for Taiwan were retrieved from the Taiwan National Development Council. The World Bank data were missing population projections for some countries; future populations for these countries were predicted using the average population growth rate in the last five years of available data.
In scenario 1, all countries continue consuming at their per capita rate of antibiotic use in 2015, accounting for changes in population. In scenario 2, all countries' per capita antibiotic consumption continues increasing at current growth rates. Current growth rate was defined as the compound annual growth rate in per capita antibiotic use in each country between 2010 and 2015. In scenario 3, all countries converged to the 2015 global median per capita antibiotic use rate by 2020, and then continued to consume at this global median through 2030 ( Figure 5 ). Figure 1 . 
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